NOT FDA-APPROVED

Semax + Selank Blend

The two cousin Russian peptides stacked into one nasal spray. Semax for cognitive lift, Selank for the anxiolytic counterweight. The most-discussed Russian-tradition nootropic combination, with all the same caveats as the individual peptides.

The 30-second read

Semax and Selank come from the same Russian peptide-research tradition (the Khavinson group), and they're frequently stacked because their effects sit on opposite ends of the nootropic spectrum: Semax pushes cognitive sharpness and focus through BDNF/NGF elevation; Selank dampens anxiety through GABA and serotonergic pathways without sedation. The pitch is "clarity without the edge." Both are approved as prescription drugs in Russia and used as nasal sprays. Neither is FDA-approved. There are zero published clinical trials of the specific combination — the stack is community wisdom built on the individual peptides' Russian clinical histories. The mechanism logic is reasonable; the rigorous evidence for the combo specifically doesn't exist.

Why this combination is on people's radar

The nootropic and biohacker communities have been pairing Semax and Selank for years. The pitch is straightforward: most cognitive-enhancement compounds either sharpen focus at the cost of agitation (caffeine, modafinil, racetams in some people) or calm anxiety at the cost of cognitive dulling (benzodiazepines, sedating antihistamines, alcohol). Semax + Selank is positioned as the rare combination that does both halves — lift cognition without the jitter, settle anxiety without the fog.

Both peptides come from the same Russian peptide-research lineage developed by Khavinson, Ashmarin, and colleagues from the 1970s onward. Both are short ACTH-derived sequences; both are typically delivered intranasally; both have been registered prescription drugs in Russia for decades. The cousin-peptide relationship is what makes the combination feel natural in protocols — same delivery route, same timing windows, same Russian clinical-evidence base.

What's missing from the picture: any clinical trial of the specific combination. The Russian clinical literature evaluates Semax and Selank individually for stroke recovery, cognitive impairment, generalized anxiety, and stress-related conditions. The "stack" is built on extrapolation from those individual records, not on a study that actually combined the two and measured outcomes.

What people are usually trying to do with it

Most people exploring this stack are after one of these:

  • Sustained focus and mental clarity through high-stress workdays
  • Reduced background anxiety without the sedation of conventional anxiolytics
  • A nootropic combination that doesn't carry dependency risk like benzodiazepines
  • Better cognitive performance under emotional or social pressure
  • A daily-use stack with broad-mechanism coverage rather than single-target action
  • Recovery from a cognitively demanding period (intense work, study, or post-illness brain fog)

What the science actually shows

Each peptide individually has a real Russian clinical record. The combination has none. Plain-English summary:

No human trials of the combination

There are zero published human clinical trials of the specific Semax + Selank combination. Anything anyone says about the stack's combined effectiveness is extrapolated from individual-peptide research and from anecdote.1

Semax individual research

Multiple Russian clinical studies report cognitive and neuroprotective effects in stroke recovery, vascular cognitive impairment, and post-concussion syndromes. The mechanism (BDNF/NGF elevation) is biologically coherent. Full Semax explainer →2

Selank individual research

Russian clinical trials in generalized anxiety disorder report anxiolytic effect comparable to medazepam (a benzodiazepine) without sedation, memory impairment, or dependence. Mechanism involves GABA-A modulation, serotonergic effects, and immune signaling. Full Selank explainer →3

Mechanistic complementarity (theoretical)

BDNF/NGF (Semax) and GABA/serotonin modulation (Selank) work on different neural systems. The theoretical case for combining them is that they target distinct mechanisms without obvious receptor or signaling conflicts. No trial has tested whether the theoretical complementarity translates to additive or synergistic effects in humans.4

What hasn't been demonstrated

That the combination produces better real-world outcomes than either peptide alone. That the stack is safe long-term in healthy adults using it daily. That the cognitive-and-anxiolytic effects translate from the clinical Russian populations (stroke, anxiety disorders) to healthy people seeking nootropic enhancement.

The honest read

What's solid:

Each peptide individually has a substantial Russian clinical record — Semax for stroke recovery and cognitive support, Selank for anxiety. The mechanisms (BDNF/NGF for Semax, GABA/serotonin modulation for Selank) are biologically real and target distinct pathways. The intranasal delivery is efficient for both. Both have favorable tolerability records in published Russian use over decades.

What's still unproven:

Anything about the combination specifically. There are no head-to-head trials, no combination pharmacokinetic studies, no controlled comparisons of the stack versus either peptide alone. The healthy-adult cognitive-enhancement use case — what most non-Russian users are doing with this stack — is also the weakest-evidenced application for both peptides individually. Independent Western RCT replication is limited for either compound.

What's hyped beyond the evidence:

"Limitless"-style claims about cognitive enhancement. The stack-is-better-than-the-individual-parts framing without trial data to support it. Treating it as a substitute for proper evaluation of moderate or severe anxiety, persistent cognitive symptoms, or post-concussion problems — those need clinical workup, not a peptide protocol. The Russian comparator data is interesting but not comprehensive, and stacking peptides on top of that doesn't make the combined claim stronger than the individual claims.

Things to know if you're looking into it

  • Two peptides, one route: the Semax + Selank blend is typically used as a single intranasal nasal spray containing both peptides in a 1:1 ratio. Some research-community protocols use them as separate sprays at the same time instead.
  • Russian clinical heritage: both peptides come from the same Russian research tradition (Khavinson group). Both are registered prescription drugs in Russia for distinct indications — Semax for stroke and cognitive disorders, Selank for anxiety.
  • Different mechanisms, complementary on paper: Semax acts via BDNF/NGF elevation (cognitive, neuroprotective). Selank acts via GABA-A modulation, serotonergic effects, and immune signaling (anxiolytic). The theoretical case for combining them rests on this mechanistic complementarity.
  • Regulatory status: neither peptide is FDA-approved. Neither is on the FDA Category 2 list as of 2026. Approved in Russia under their respective brand names.
  • Reported tolerability: generally favorable for both individual peptides in published Russian use. Combination tolerability isn't separately characterized but isn't reported as different from individual use.
  • Don't dose Semax late in the day: Semax's cognitive-stimulant effect can interfere with sleep onset if dosed past mid-afternoon. Selank's anxiolytic effect doesn't carry the same constraint — this is a key practical asymmetry between the two when run as a stack.
  • Healthcare provider involvement: recommended for any decision about use, especially for persistent cognitive or anxiety symptoms that warrant proper evaluation.
  • Component breakdowns: see the dedicated Semax and Selank pages for full mechanism, dosing, and reference detail. The "Want to go deeper?" section below summarizes the blend-specific considerations.

Reconstitution & dose calculator

1:1 Semax + Selank blend. Both approved in Russia, neither FDA-approved. Zero published human studies on the specific combination. The dose math below uses combined peptide mass — a 500 mcg dose means 250 mcg of Semax plus 250 mcg of Selank. Both are primarily intranasal peptides; the calculator shows volume per dose, which intranasal users translate to drops or sprays based on their delivery device. Most published clinical use is intranasal, not subcutaneous. This is an educational reference, not dosing guidance.
Suggested start
500 mcg/dose
250 mcg of each peptide
Common range
500–1000 mcg/dose
250–500 mcg of each, 1–2× daily
Max dose
2000 mcg/dose
1000 mcg of each — nootropic ceiling
Cycle
2–4 wks on
Then 1–2 weeks off
mL
Defaults to 5 mg/mL combined (4 mL into the 20 mg total vial) — matches the standard Semax and Selank standalone reconstitution. Standard 500 mcg combined dose lands at 10 syringe units (or 1 spray on a typical 100 µL nasal-spray bottle, 2 sprays on a 50 µL bottle).
mcg
Intranasal (standard) or subcutaneous. The dose is combined — 500 mcg = 250 mcg Semax + 250 mcg Selank. Most protocols dose 1–2× daily, morning to early afternoon. Don't dose past mid-afternoon — Semax's cognitive-stimulant effect can disrupt sleep onset if dosed late.
Concentration
5.0 mg/mL
Per dose (volume)
0.10 mL
10 units on insulin syringe (SubQ)
Doses per vial
~40
~40 days (~5.7 weeks) of daily dosing

When to stay put vs. adjust

Stay put at 500 mcg combined in the morning for the first 1–2 weeks. The blend's effects build subtly — sharper focus from Semax over days as BDNF/NGF signaling responds, smoother background mood from Selank within the first few doses. Neither half produces the obvious sensation you'd get from a stimulant or benzodiazepine, and that subtlety is by design. Give the stack a real trial window before deciding either component isn't working.

Consider stepping to 1000 mcg combined or adding a second daily dose (early afternoon, no later) only after at least one week with clear tolerability and no perceived effect. Two smaller doses spread across the day often outperform one larger dose for both components — both peptides have relatively short half-lives, so coverage is more about pulse frequency than single-dose magnitude.

The Semax-timing constraint is the most important practical detail. Semax can disrupt sleep if dosed past mid-afternoon — this is the most common reason people conclude the stack "doesn't work" when really the problem is sleep fragmentation from late dosing. Selank doesn't have this constraint; if you want anxiolytic coverage in the evening, dose Selank alone at that time rather than the combined blend.

Watch for mild nasal irritation, occasional metallic taste (from Selank), or sleep disruption if dosed too late. Both components are well-tolerated in published Russian clinical use. Combination-specific tolerability isn't separately characterized but reports don't suggest different patterns than individual use.

Don't go above 2000 mcg combined per administration. Russian clinical protocols for severe indications (acute stroke, severe anxiety) use higher doses but those are clinical settings with monitored populations. For nootropic-style daily use in healthy adults, doses above this exit common protocols without clear added benefit.

Cycle off at the 2–4 week mark for 1–2 weeks. Russian protocols are typically course-based rather than continuous. The off-cycle helps prevent receptor adaptation that can blunt the effect over time, and it's also a moment to evaluate whether the underlying issue (cognitive demand, anxiety pattern) needs other forms of support.

The honest read. Each peptide individually has a real Russian clinical record — Semax for cognitive/stroke recovery, Selank for anxiety. The mechanism logic for combining them is reasonable on paper. What's missing is any controlled trial of the combination specifically. Anyone using the blend is treating it as a sum-of-parts intervention based on extrapolation from the individual records, not on combination evidence. The healthy-adult nootropic use case — what most non-Russian users are doing with this stack — is the weakest-evidenced application for both halves individually. The combination doesn't make those individual evidence gaps go away.

For educational and research purposes only. This is not medical advice. Both Semax and Selank are approved as prescription drugs in Russia but neither is FDA-approved. There are zero published human trials of the specific combination. Most published clinical evidence is from Russian institutes; Western replication is limited. Persistent cognitive or anxiety symptoms warrant evaluation by a licensed clinician. Consult a healthcare provider before any health decision.

What people often ask

Why combine Semax and Selank instead of using either alone?

The two peptides target different systems — Semax for cognitive support via BDNF/NGF, Selank for anxiety via GABA and serotonergic pathways. People who want both effects (sharper focus and reduced background anxiety) sometimes find that one peptide alone doesn't cover both. The combination is community-driven; there's no clinical trial showing the stack outperforms either peptide alone.

Is the blend more effective than using each peptide separately?

Honestly, no one knows. The mechanism logic suggests the effects could be complementary, but no published study has compared the combination head-to-head against either peptide alone. Subjective community reports vary widely.

What's the timing for the blend?

Standard protocols are once or twice daily, with the morning dose being primary. The most important constraint: don't dose the blend past mid-afternoon, because Semax's cognitive-stimulant effect can disrupt sleep onset. Selank alone is fine in the evening if anxiety is interfering with sleep.

Can I use just one of them in the evening?

Yes — some protocols pair the morning combined dose with an evening Selank-only dose for anxiolytic coverage at sleep onset. Adding evening Semax is the common mistake that creates sleep problems.

How long until I notice anything?

The Selank anxiolytic effect can register within the first few doses for some users. Semax's cognitive effects build over a week or more as BDNF/NGF signaling responds. Give the stack at least 1–2 weeks at the standard dose before deciding it isn't working.

Are there side effects I should watch for?

Both peptides individually have favorable tolerability records in Russian clinical use. Common reports: mild nasal irritation, occasional metallic taste (more often from Selank), and sleep disruption if dosed too late. Serious side effects are uncommon in published use.

Is the blend FDA-approved?

No. Neither peptide is FDA-approved individually, and the combination has not been evaluated by FDA in any form. Both are approved as prescription drugs in Russia under their individual brand names.

FDA and regulatory status

Status as of May 11, 2026: Neither Semax nor Selank is FDA-approved for any consumer indication. Both are approved as prescription drugs in Russia — Semax (1990s) for stroke recovery, cognitive disorders, and ADHD-like conditions; Selank (2009) for generalized anxiety. Neither is on the FDA Category 2 list. The combination has not been evaluated by any major regulatory body. Status updates land here when they happen.

Want to go deeper? Mechanism complementarity, intranasal delivery considerations, half-life details, and references. Click to expand.

Mechanism of action (combined)

The blend's theoretical case rests on the two peptides' distinct mechanisms operating in complementary brain systems without obvious receptor or signaling conflicts.

Semax: BDNF and NGF elevation

Semax is a 7-amino-acid peptide derived from a fragment of ACTH, modified to preserve cognitive effects without HPA-axis activation. Mechanistic studies show elevation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), the same growth factors associated with the cognitive benefits of exercise, antidepressant effects of SSRIs over time, and neuroplasticity in general.

Selank: GABA-A modulation, serotonergic effects, immune signaling

Selank is a 7-amino-acid peptide derived from tuftsin (an immune-modulating fragment). Mechanistic studies suggest GABA-A receptor expression changes, serotonergic neurotransmission effects, and immune-stimulating activity. The anxiolytic effect appears to operate through GABA pathways without direct receptor binding (different from how benzodiazepines work).

Theoretical complementarity

The two mechanisms operate on different neurotransmitter systems and growth-factor pathways. The mechanistic case for combining them is that the effects should be additive rather than competing. No published research has tested whether this theoretical complementarity translates to additive or synergistic effects in humans.

Studied dosing protocols

Combination not formally studied. The dosing summary below describes how the individual peptides are used in Russian clinical settings and how the combination is run in research-peptide circles. There are no published combination-specific dose-finding studies.

Russian clinical individual use: Semax 0.1% nasal spray (1 mg/mL) for cognitive/neuroprotective indications, typically 200–1000 mcg/dose 1–3× daily. Selank 0.15% nasal spray (1.5 mg/mL) for anxiety, typically 250–750 mcg/dose 1–3× daily. Combination community use mirrors these ranges with a 1:1 ratio.

Research-community blend dosing: 250–500 mcg of each peptide per dose (500–1000 mcg combined), 1–2× daily, morning and early afternoon. Higher doses occasionally used but exit common nootropic protocols.

Cycle pattern: 2–4 weeks on, 1–2 weeks off. Continuous use isn't validated; the cycle pattern follows Russian clinical course-based protocols.

Half-life and timing

Both Semax and Selank have relatively short plasma half-lives (Semax ~30 minutes, Selank ~30 minutes). The intranasal route bypasses first-pass metabolism and provides relatively rapid CNS availability via the nasal mucosa. The short half-life is why most protocols dose 1–2× daily for sustained coverage rather than once-daily large doses.

The asymmetric timing constraint: Semax's cognitive-stimulant character can disrupt sleep onset if dosed past mid-afternoon (typically >3 pm). Selank doesn't share this property — the anxiolytic effect doesn't fight sleep, and some users specifically dose Selank in the evening for sleep-onset anxiety. This means the combined blend should generally be morning-only or morning + early-afternoon, with any evening dosing being Selank-only rather than the blend.

Side effects and safety profile

Both peptides individually have favorable safety profiles in published Russian clinical use over decades. Most-reported effects:

  • Mild nasal irritation (intranasal route, both peptides)
  • Occasional metallic taste in the mouth (more often reported with Selank)
  • Sleep disruption if Semax is dosed late in the day
  • Rare reports of mild fatigue at higher doses (Selank)
  • Headache (uncommon, both peptides)

Combination-specific safety isn't separately characterized in published literature. Long-term safety data in healthy adults using continuous nootropic-style protocols (rather than the course-based Russian clinical pattern) is limited for both peptides.

References

  1. PeptideLibraryHub editorial review (2026). No published human trials of the specific Semax + Selank combination identified in PubMed or Russian-language clinical literature databases as of May 2026.
  2. Kaplan AY, Kochetova AG, Nezavibathko VN, et al. (1996). "Synthetic ACTH analogue Semax displays nootropic-like activity in humans." Neuroscience Research Communications, 19(2), 115–123. PubMed
  3. Zozulia AA, Neznamov GG, Siuniakov TS, et al. (2008). "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia." Zh Nevrol Psikhiatr Im S S Korsakova, 108(4), 38–48. PubMed
  4. Khavinson VKh, Malinin VV. (2005). "Gerontological aspects of genome peptide regulation." Karger Medical and Scientific Publishers. ISBN 3-8055-7873-7.
For educational and research purposes only. This is not medical advice. Neither Semax nor Selank is FDA-approved; both are approved as prescription drugs in Russia. There are zero published human clinical trials of the specific combination. Consult a licensed healthcare provider before considering any peptide. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.